Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers

Journal of the National Cancer Institute

Volumn 99, Issue 16, 2007, Pages 1248-1256

  Schairer, Catherine ^a   Hisada, Michie ^a   Chen, Bingshu E ^a   Brown, Linda M ^a   Howard, Regan ^a   Fosså, Sophie D ^b   Gail, Mitchell ^a   Travis, Lois B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANUS CANCER; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESOPHAGUS CANCER; ETHNICITY; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOUTH CANCER; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RECTUM CANCER; STOMACH CANCER; TESTIS CANCER;

ADULT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; TESTICULAR NEOPLASMS;

EID: 34548141825     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm081     Document Type: Article

References (35)

1. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;4:3274-80.
2. Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, et al. EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14(Suppl 5):v128-49.
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review. 1975-2000. Bethesda (MD): National Cancer Institute; 2003. Available at: http://seer.cancer.gov. [Last accessed: October 23, 2006.]
4. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65.
5. Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71.
6. Nieder C, Milas L, Ang KK. Tissue tolerance to reirradiation. Semin Radiat Oncol 2000;10:200-9.
7. Robinson E, Neugut AI. Clinical aspects of multiple primary neoplasms. Cancer Detect Prev 1989;13:287-92.
8. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005;44:13-22.
9. Tibbs MK. Wound healing following radiation therapy: A review. Radiother Oncol 1997;42:99-106.
10. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;4:943-55.
11. Claij N, te Riele H. Microsatellite instability in human cancer: A prognostic marker for chemotherapy? Exp Cell Res 1999;246:1-10.
12. World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva (Switzerland): World Health Organization; 2000.
13. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs excluding AK/AZ, Nov 2004 Sub for White/Black/Other (1973-2002 varying) - Linked to County Attributes - Total U.S., 1969-2002 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released December 2004, based on the November 2004 submission. Available at: http://seer.cancer.gov. [Last accessed: October 23, 2006.]
14. Seiffert JE, editor. SEER program: Comparative staging guide for cancer. Bethesda (MD): National Institutes of Health (NIH publication no. 93-3640); 1993.
15. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol 1. 8th Rev. Geneva (Switzerland): World Health Organization; 1967.
16. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol 1. 9th Rev. Geneva (Switzerland): World Health Organization; 1977.
17. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Vol 1. 10th rev. Geneva (Switzerland): World Health Organization; 1992.
18. Thomas G. Over 20 years of progress in radiation oncology: Seminoma. Semin Radiat Oncol 1997;7:135-45.
19. Cox DR, Oakes D. Analysis of survival data. London (U.K.): Chapman and Hall; 1984.
20. SAS Institute Inc. SAS Online Doc, version 8. Cary (NC): SAS Institute Inc; 1999.
21. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-44.
22. Hanks GE, Peters T, Owen J. Seminoma of the testis: Long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992;24:913-9.
23. Fosså SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. J Clin Oncol 1999;17: 1146-54.
24. Jones W, Fosså S, Mead GM, Roberts TJ, Sokal M, Horwich A, et al. A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18): Preliminary report. In: Harnden P, Joffe JK, Jones WG, editors. Germ cell Tumours V. London (U.K.): Springer; 2002. p. 235-6.
25. Jones WG, Fosså SD, Mead GM, Roberts TJ, Sokal M, Horwich A, et al. A randomized trial of 30 Gy vs 20 Gy in the adjuvant treatment of stage I testicular seminoma (MRC TE18, EORTC 30942, ISRCTN18525328). J Clin Oncol 2005;23:1200-8.
26. Dormand EL, Banwell PE, Goodacre TE. Radiotherapy and wound healing. Int Wound J 2005;2:112-27.
27. Behrens C, Travis LB, Wistuba II, Davis S, Maitra A, Clarke EA, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev 2000;9: 1027-35.
28. Horwich A, Bell J. Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol 1994;30:193-8.
29. Fosså SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004;90:607-12.
30. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640-7.
31. Neugut AI, Robinson E, Nieves J, Murray T, Tsai W-Y. Poor survival of treatment-related acute nonlymphocytic leukemia. JAMA 1990;264: 1006-8.
32. Koppe MJ, Zoetmulder FAN, van Zandwijk N, Hart AAM, Baas P, Rutgers EJTh. The prognostic significance of a previous malignancy in operable non-small cell lung cancer. Lung Cancer 2001;32:47-53.
33. Bhattacharyya N, Nayak VK. Survival outcomes for second primary head and neck cancer: A matched analysis Otolaryngol Head Neck Surg 2005; 132:63-8.
34. Robinson E, Neugut AI, Murray T, Rennert G. A comparison of the clinical characteristics of first and second primary head and neck cancers. Cancer 1991;68:189-92.
35. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973-2000 (NIH publication no. 05-5302). Bethesda (MD): National Cancer Institute; 2006.